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A literature review of UK medical meetings during a similar time period revealed variable rates of eventual publication. Weale et al 2 found publication rates of 24-54% across four surgical meetings. A study of emergency medicine identified a publication rate of 30%, with platform presentations more likely to be published. 3 Oral and maxillofacial surgery abstracts from 2001 to 2007 were published in 24% of cases, with scientific versus clinical presentations more likely to achieve eventual publication. 4 Urology abstracts from 2001 to 2002 were published in 42% cases. 5 Strengths of our study include surveying a large number of abstracts, a relatively long follow-up time and a robust search methodology consistent with previous work on this subject. A potential limitation is that we were unable to determine how many abstracts were submitted for full publication but eventually rejected, or never submitted at all, as this would have required extensive surveying of all authors presenting at the ABN. Our findings emphasise the importance of collaborative work in achieving high-quality research and publication. However, it is possible that this represents a surrogate of other factors, for example case reports may be likely to be single-centre work. While impact factors are a controversial metric of research quality, the majority of eventually published work following presentation at the ABN contributed to the scientific literature in the form of subsequent citations.
INTRODUCTION
Hereditary spastic paraplegias (HSPs) are a group of disorders characterised by slow progressive weakness and spasticity of the lower limbs. HSPs have been divided into pure and complicated forms, depending 
METHODS
The currently living family members were examined by movement disorder specialists (TLG, GAM, RM and AO). Neurological assessments, including the Spastic Paraplegia Rating Scale (SPRS) 2 Mental Deterioration Battery (MDB) 3 electrophysiology of peripheral nerves, and neuroimaging analyses, were carried out. After informed consent was given, genomic DNA was extracted from peripheral lymphocytes. Genetic analyses were conducted as described in online supplementary data, including linkage studies at the currently known ADHSP loci, PCR-direct sequencing, PCR-restriction fragment length polymorphism (PCR-RFLP) assay, and in silico analysis.
RESULTS
The RM 551 family is composed of a three-generation kindred with AD inheritance. Eleven individuals were diagnosed as 'certainly affected' and classified as having complicated HSP. 1 At examination, the age range of the affected individuals was 19-77 years (mean±SD=40.4±17.9 years). Spastic paraparesis was the primary symptom in the clinical course of each patient; age at onset ranged between 12 and 55 years (mean±SD=32.2± 15.0 years). The decrease of age at onset between successive generations ranged from 4 to 39 years per generation. The disease was slowly progressive and urinary urgency was a common symptom. Electroneurography of both motor and sensory nerves, as well as electromyography, were normal. MDB did not show cognitive impairment. Other clinical features associated with SPG10 1 were absent. figure  S1 ). DD and VV were absent in all members of the family who did not have gait difficulty. The environmental associations of DD, such as alcohol consumption, tobacco exposure, manual activities, retractile capsulitis, epilepsy, diabetes, HIV and dyslipidemia, 5 were absent in all patients. Obesity and lower limb deep vein thrombosis examined by venous ultrasonography were also absent, suggesting a primary form of VV. 4 Significant logarithm of odds (LOD) scores were obtained at the SPG10 locus only (Z max =4.56 at θ=0.0 at the microsatellite marker D12S1724, online supplementary table S1) and a novel heterozygous change in exon 6 (c.484C>T) was found, resulting in amino acid substitution of arginine to tryptophan at codon 162 ( p.R162W). The PCR-RFLP analysis demonstrated a complete cosegregation of the mutation with the disease and the nucleotide change is predicted to cause the disease, as well as influence the protein function by in silico analysis (see online supplementary figure S2 and table S2).
DISCUSSION
To date, 21 mutations have been reported in SPG10/KIF5A. Most of the mutations locate within the kinesin motor domain and are missense mutations, except from one in-frame deletion mutation N256del. The residues p.R204, p.N256 and p.R280 are mutational hot spots (see online supplementary figure S3). Neither nonsense nor frameshift mutations leading to truncated proteins are reported. These data suggest that SPG10 pathogenesis is not simply due to haploinsufficiency. A dominant negative effect has been postulated in SPG10 pathogenesis. The novel missense mutation, p.R162W, would lead to altering the conformation of the kinesin-1 complex and disrupting cargo transportation along the axon.
Other kinesin isotypes, KIF1A and KIF1C, have been reported as causative genes of SPG30 and spastic ataxia 2 (SAX2 or SPG58), respectively. This indicates that the underlying pathological mechanism in spastic paraplegia caused by PostScript mutations in the kinesin gene family varies depending on the basis of the isotype. Moreover, HSP-related proteins interact with each other, including myelin proteolipid protein 1, atlastin-1, kinesin-HC5A, kinesin-3, REEP1, KIF1C and reticulon proteins. Mutations in KIF5A might further affect the biological pathway revealed by such interactions leading to motoneuron degeneration, as described in the Drosophila model. 6 Additional clinical features observed in the family, such as VV and DD, might be explained by two potential pathological mechanisms. The genetic factor(s) for developing VV and/or DD might exist within the approximately 7.5 cM interval encompassed by the two microsatellite markers, D12S270 and D12S1601. Developmental abnormalities, including vessel malformation, were observed in an individual with chromosomal deletion of 1.76-Mb comprising the SPG10 locus 7 suggesting that there might be genetic predisposing factor(s) for fragility of the blood vessel within the region. Considering the histopathology in DD, genes involved in myofibroblast regulation, extracellular matrix or collagen might be a candidate for developing the disease. The OS-9 gene, encoding osteosarcoma amplified 9, has been mapped 143-kb away from KIF5A [National Center for Biotechnology Information (NCBI) website at http://www.ncbi.nlm.nih. gov/]. The gene expression was coamplified with the cyclin-dependent kinase 4 (CDK4) gene in sarcoma tissues. 8 Dysregulation of the gene might be involved in DD observed in the patients. The other possibility is that the combined phenotypic features might be due to the coexistence of the KIF5A mutation and other genetic variation(s) mapped to region(s) away from the SPG10 locus. There is a growing body of evidence that expression of the transforming growth factor β (TGFβ) is elevated in Dupuytren's fibroblasts. 9 Further investigation of genetic variations at the promoter region of TGFβ is needed to confirm the genetic model.
In conclusion, this study demonstrates further allelic heterogeneity, thus expanding the clinical-genetic spectrum of SPG10.
